​

Biomea Fusion Stock (NASDAQ:BMEA)

ForecastRevenueOwnershipFinancialsChart
Biomea Fusion by TradingView

Previous Close

$2.90

52W Range

$1.29 - $13.07

50D Avg

$1.93

200D Avg

$4.96

Market Cap

$71.76M

Avg Vol (3M)

$2.17M

Beta

-0.25

Div Yield

-

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

79

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-144.07M$-126.14M$-83.63M
Net Income$-138.43M$-117.25M$-80.02M
EBITDA$-144.07M$-124.62M$-82.94M
Basic EPS$-3.83$-3.44$-2.73
Diluted EPS$-3.83$-3.44$-2.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
DSGNDesign Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
IKNAIkena Oncology, Inc.